# BioMarin

递送平台 — 载体工程化.

Source: https://cn.bioecon.ru/companies/biomarin/
Updated: 2026-07-02

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 为收购Amicus Therapeutics提供$3.7 billion债务融资，其中包括2026年2月发行的$850 million高级无抵押票据 (2025-12-31) | https://www.sec.gov/Archives/edgar/data/1048477/000130817926000313/bmrn015087_ars.pdf |
| 产能 | valoctocogene roxaparvovec与BMN 307合计年产10,000剂 (2020-09-24) | https://www.biomarin.com/news/press-releases/biomarin-announces-6-presentations-at-american-society-of-gene-and-cell-therapy-asgct-virtual-2021-annual-meeting/, https://www.biomarin.com/news/press-releases/biomarin-pioneer-in-phenylketonuria-to-begin-clinical-trial-with-bmn-307-gene-therapy/, https://www.prnewswire.com/news-releases/biomarin-pioneer-in-phenylketonuria-pku-and-gene-therapy-doses-first-participant-in-global-phearless-phase-12-study-of-bmn-307-gene-therapy-301137556.html |
| 认证 | 两处生产基地均通过ISO 14001和ISO 45001认证 (2024-01-19) | https://www.biomarin.com/science/manufacturing/ |
| 认证 | 位于加利福尼亚州Novato的载体生产设施获EMA cGMP认证 (2020-06-30) | https://www.prnewswire.com/news-releases/biomarin-pioneer-in-phenylketonuria-pku-and-gene-therapy-doses-first-participant-in-global-phearless-phase-12-study-of-bmn-307-gene-therapy-301137556.html |
| 营收 | 2025全年为$3.221 billion (2025-12-31) | https://investors.biomarin.com/news/news-details/2026/BioMarin-Reports-Fourth-Quarter-and-Full-year-2025-Financial-and-Operating-Results/default.aspx, https://www.sec.gov/Archives/edgar/data/1048477/000130817926000313/bmrn015087_ars.pdf |
| 生产基地 | 美国加利福尼亚州诺瓦托 | https://www.biomarin.com/contact-us/locations/, https://www.biomarin.com/science/manufacturing/ |
| 生产基地 | 爱尔兰科克郡尚巴利（Shanbally） | https://www.biomarin.com/contact-us/locations/, https://www.biomarin.com/science/manufacturing/ |

独立来源: prnewswire.com, sec.gov